Laroprovstat not checked
AstraZeneca · AZD0780 · Dose 1
FollowEvery change as it happens, and a Monday email
Trials
6 active
20 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “daily oral dose of the Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1”In the company’s words, NCT07619131 on ClinicalTrials.gov
- Tested for
- Cardiovascular Disease (2 trials), Heterozygous Familial Hypercholesterolaemia, Hypercholesterolaemia, Hypercholesterolemia, Dyslipidaemia
- Main trialPhase 3
- “This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56…”In the company’s words, NCT07000136 on ClinicalTrials.gov
- Other names
- AZD0780 · Dose 1
Other drugs for Cardiovascular Disease
- MezigdomideCelgene · Phase 3
- Neuroncell-EXCytopeutics Sdn. Bhd. · Phase 2/3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- MilvexianJanssen Research & Development, LLC · Phase 3
- Baxdrostat/dapagliflozinAstraZeneca · Phase 3
- VicagrelJiangsu vcare pharmaceutical technology co., LTD · Phase 3
Coming up6
- 4 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 11 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 22 Feb 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 30 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 11 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 26 Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 13 NovCompletion date moved: 2025-07-03 to 2027-02-22 · ClinicalTrials.gov NCT06834932
- 12 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07930507
Trials20
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 4 Jan 2027 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | |
| Phase 3Active, not recruiting | 11 Jan 2027 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | |
| Phase 3Recruiting | 30 Jul 2027 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. | |
| Phase 3Not yet recruiting | 11 Oct 2027 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients | |
| Phase 3Recruiting | 26 Oct 2029 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | |
| Phase 2/3Active, not recruiting | 22 Feb 2027 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | |
| Phase 2Completed | 30 Sep 2024 | A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia | |
| Phase 2Completed | 18 Apr 2025 | A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure | |
| Phase 2Completed | 3 Sep 2026 | A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia | |
| Phase 1Completed | 15 May 2023 | A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. | |
| Phase 1Completed | 6 Jun 2023 | An ADME Study of [14C]AZD0780 in Healthy Male Subjects | |
| Phase 1Completed | 14 Jun 2024 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects | |
| Phase 1Completed | 8 Nov 2024 | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 | |
| Phase 1Completed | 1 Dec 2024 | A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 | |
| Phase 1Completed | 17 Feb 2025 | An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions | |
| Phase 1Completed | 29 Oct 2025 | A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. | |
| Phase 1Completed | 30 Dec 2025 | A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years | |
| Phase 1Completed | 5 Jun 2026 | A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults | |
| Phase 1Completed | 29 Jun 2026 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels | |
| Phase 1Completed | 8 Jul 2026 | A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026